Bristol Myers Opdivo Wins The EC Approval for GEJ Cancer

Bristol Myers Opdivo Wins The EC Approval for GEJ Cancer

The European Commmision (EC) has granted Bristol Myers approval for Opdivo (nivolumab) to treat adult esophageal or gastroesophageal junction (GEJ) cancer who have pathologic disease after previous neoadjuvant chemoradiotherapy (CRT).  With the approval based on the...
Canada Approves BeiGene BRUKINSA for Mantle Cell Lymphoma

Canada Approves BeiGene BRUKINSA for Mantle Cell Lymphoma

Health Canada has granted BeiGene approval for BRUKINSA (Zanubrutinib) to treat mantle cell lymphoma (MCL) in adults who have already received at least one other prior treatment. As global, science-driven biotechnology company, BeiGene focuses on improving treatment...